KLK3 and Familial prostate cancer: This has resulted in identification of α2, 3-sialylated PSA as a marker for discriminating patients with high-risk prostate cancer from those with benign prostatic hyperplasia and low-risk prostate cancer, with higher levels of sensitivity and specificity.